TR201808818T4 - Gip reseptör aktivitesi sergileyen glukagon analogları. - Google Patents
Gip reseptör aktivitesi sergileyen glukagon analogları. Download PDFInfo
- Publication number
- TR201808818T4 TR201808818T4 TR2018/08818T TR201808818T TR201808818T4 TR 201808818 T4 TR201808818 T4 TR 201808818T4 TR 2018/08818 T TR2018/08818 T TR 2018/08818T TR 201808818 T TR201808818 T TR 201808818T TR 201808818 T4 TR201808818 T4 TR 201808818T4
- Authority
- TR
- Turkey
- Prior art keywords
- amino acid
- peptide
- ala
- seq
- acetyl
- Prior art date
Links
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title claims abstract 6
- 230000000694 effects Effects 0.000 title claims abstract 4
- 108020003175 receptors Proteins 0.000 title claims 3
- 102000005962 receptors Human genes 0.000 title claims 3
- 230000001747 exhibiting effect Effects 0.000 title 1
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 claims abstract 4
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 31
- 150000001413 amino acids Chemical class 0.000 claims 30
- -1 Acetyl D-His Chemical compound 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 238000012986 modification Methods 0.000 claims 6
- 230000004048 modification Effects 0.000 claims 6
- 230000002378 acidificating effect Effects 0.000 claims 5
- 239000000539 dimer Substances 0.000 claims 5
- 101001015516 Homo sapiens Glucagon-like peptide 1 receptor Proteins 0.000 claims 4
- 125000003892 C18 acyl group Chemical group 0.000 claims 3
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims 2
- 102000051325 Glucagon Human genes 0.000 claims 2
- 108060003199 Glucagon Proteins 0.000 claims 2
- 101000886868 Homo sapiens Gastric inhibitory polypeptide Proteins 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 229960004666 glucagon Drugs 0.000 claims 2
- 102000050325 human granulocyte inhibitory Human genes 0.000 claims 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims 2
- 230000004584 weight gain Effects 0.000 claims 2
- 235000019786 weight gain Nutrition 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 claims 1
- SCOZOHWKTFBYNS-UHFFFAOYSA-N 2,2-diamino-3-methyl-4-oxopentanoic acid Chemical compound CC(=O)C(C)C(N)(N)C(O)=O SCOZOHWKTFBYNS-UHFFFAOYSA-N 0.000 claims 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 claims 1
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims 1
- 101001040075 Homo sapiens Glucagon receptor Proteins 0.000 claims 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 claims 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 claims 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 claims 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 claims 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 claims 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 claims 1
- 108010077895 Sarcosine Proteins 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 229940043230 sarcosine Drugs 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Abstract
Burada, GIP reseptöründe kuvvetli aktivite sergileyen ve diyabet ve obezitenin tedavisinde kullanım için tasarlanmış glukagon analogları sağlanmaktadır. Örnek uygulamalarda, mevcut tarifnamenin glukagon analoğu, nanomolar veya pikomolar aralık içinde olan GIP reseptöründe bir EC50 sergilemektedir.
Claims (15)
- ISTEMLER (SEQ ID NO: 140) sekansini ihtiva eden bir peptit olup, özelligi; I) Xi'in, natif glukagonun l pozisyonuna karsilik gelmesi ve X1'in, asagidakilerden olusan gruptan seçilmesidir: Asetil D- His, Asetil D-Tyr, Asetil D-Phe, Desamino Tyr, D-His, ve D- Xz'nin, Ala, Gly,Pro, sarkozin, Ser ve Val olmasi, X3'ün, Gln, yapi I, II veya III'ün bir yan zincirini ihtiva eden bir amino asit, bir hidrofobik amino asit, bir asidik amino asit veya bir bazik amino asit olmasidir veya asagidakilerden olusan gruptan seçilen bir amino asit olmasidir: Glu, Ala, Leu, lle, Nle, Val, NorVal, homoserin, Met, metiyonin sülfoksit, metiyonin sülfon, asetiI-Orm asetil-diaminobutanoik asit ve asetiI-Lys; burada yapi I, II ve III'ün sunlar olmasi: burada Rl'in. Cms alkil veya Cosheteroalkil olmasi; Rz'nin, NHR4 veya C1& alkil olmasi; R3'ün, Cng alkil olmasi; R4'ün, H veya Cia alkil olmasi; X, NH, 0 veya S olmasi; ve Y, NHR& SR3 veya OR3 olmasi; Xw'un, Tyr veya bir C12 ila C18 asil veya alkil grubuna kovalent olarak bagli bir amino asittir; Xß'in, bir asidik amino asit, tercihe göre, Glu veya Asp Olmasi; Xm'nin, istege bagli olarak Gly, Pro ve Ser'den baska herhangi bir amino asittir; örnegin, Glu, Ala, alfa, alfa- diornatilmis amino asittir (örnegin, AIB), His, Lys Xu'nin, Arg, His, Gln olmasi; Xm'in, Arg veya Ala olmasi; Xm'un, Ala veya alfa, alfa diornatilmis amino asit olmasi; Xm'nin, asagidakilerden olusan gruptan seçilir: alfa, alfa- diornatilmis amino asit (örnegin, AIB) veya Gln veya His, Lys veya Ala; Xu'in, bir asidik amino asit, tercihe göre, Asp veya Glu Olmasi; Xp'nin, Leu, Ala, N|e veya Met olmasi; Xn'in, Ala veya asidik bir amino asit olmasi (tercihe göre, Asp veya Glu); Xw'un, alifatik, örnegin, Ala veya Leu veya Gly veya AIB veya Val olmasi; Xm'un, küçük alifatik amino asit, örnegin, Ala veya Gly olmasi Xß'in, Ala veya bazik bir amino asit olmasidir (tercihe göre, Arg veya Lys); burada, Xn,in asidik bir amino asit olmasi halinde, Xßiin bazik bir amino asit olmasi; burada, tercihe göre, Xzg Asp ise, Xzg'un Gly olmamasi, burada, Xio Tyr ise, peptit, 40 pozisyonunda bir C12 ila C18 asil veya alkil grubuna kovalent olarak baglanmis bir amino asidi içermesidir, ve burada tercihe göre, peptidin, 41 pozisyonunda Gly içermesi, burada peptidin C ucu amino asidinin amitlenmesidir; veya I) Xi'in, natif glukagonun l pozisyonuna karsilik gelmesi ve X1, asagidakilerden olusan gruptan seçilmesidir: Asetil D- His, Asetil D-Tyri Asetil D-Phe, Desamino Tyr, D-His ve D- Xz'nin, Ala veya Gly olmasi, X3'ün, Gln olmasi; Xm'un, C12-C18 asil veya alkil grubuna kovalent OIarak bagli bir amino asit olmasi; Xß'in, Asp olmasi; X15'nin, Glu olmasi; Xu'nin, Arg, His veya Gln olmasi; X13'in, Ala olmasi; Xw'un, Ala olmasi; Xzo'nin, Gln olmasi; Xu'in, Asp olmasi; Xn'nin, Leu olmasi; Xzs'in, Glu olmasi; Xw'un, Gly olmasi; Xm'Un, Gly olmasi Xß'in, Ala olmasidir; buradaki peptidin, insan GIP reseptöründe ve insan GLP-l reseptöründe ve/veya insan glukagon reseptöründe agonist aktivite sergilemesi, tercihe göre, burada glukagon analogunun, GIP reseptörüne karsi insan GLP-l reseptörü için lOO'den daha az seçicilige sahip olmasidir.
- 2. Istem 1 'in peptidi olup, özelligi; 1 ve 2 numarali pozisyonlarda asagidakilerden olusan gruptan seçilen bir çift amino asit içermesidir: Pozisyon 1 Pozisyon 2 Asetil D-His Ala Asetil D-Tyr Ala Desamino Tyr Ala D-HIS Ala Asetil D-Phe Ala ayrica burada Xio'un C12-C18 asil veya alkil grubuna kovalent olarak bagli bir amino asit olmasi veya Xio, Tyr oldugunda, peptidin, 40 pozisyonunda bir C12 ila C18 asil veya alkil grubuna kovalent olarak baglanmis bir amino asidi içermesi ve peptidin tercihe göre 41 pozisyonunda Gly içermesidir.
- 3. Istem l'in peptidi olup, özelligi; (ii), burada i) i pozisyonundaki amino asidin Asetil D-Tyr, Asetil D-His, DesaminoTyr, D-Tyr, D-HIS ve Asetil D-Phe arasindan seçilmesi; ii) 2 pozisyonundaki amino asidin, Ala veya Gly olmasi iii) 10 pozisyonundaki amino asidin, bir C12-C18 asil veya alkil grubuna kovalent olarak eklenmis olmasi iv) Xm'nin Gln olmasi; V) Xw ve Xn,in ikisinin de Glu olmasi; vi) Xw'in Ala olmasi; VII) X27'nin Leu olmasi, Xzg'un Gly olmasi ve peptidin C ucunda amine edilmis bir Gly ihtiva etmesidir.
- 4. Istem 1 'in peptidi olup, özelligi; SEQ ID NO: 11 sekansini içermesidir.
- 5. Istem 1 'in peptidi olup, özelligi; SEQ ID NO: 12 sekansini içermesidir.
- 6. Istem 1 'in peptidi olup, özelligi; SEQ ID NO: 13 sekansini içermesidir.
- 7. Istem 1 'in peptidi olup, özelligi; SEQ ID NO: 15 sekansini içermesidir.
- 8. Istem 1 'in peptidi olup, özelligi; SEQ lD NO: 16 sekansini içermesidir.
- 9. Istem 1 'in peptidi olup, özelligi; SEQ ID NO: 22 sekansini içermesidir.
- 10. Istem l'in peptidinin analogu olup, özelligi; bunlari içermesidir: a. SEQ ID NO: 11'e göre 3'e kadar amino asit modifikasyonlu bir SEQ ID NO: 11 sekansi; b. SEQ ID NO: 12'e göre 3'e kadar amino asit modifikasyonlu bir SEQ ID NO: 12 sekansi, c. SEQ ID NO: 13'e göre 3'e kadar amino asit modifikasyonlu bir SEQ ID NO: 13 sekansi, d. SEQ ID NO: 15'e göre 3'e kadar amino asit modifikasyonlu bir SEQ ID NO: 15 sekansi, e. SEQ ID NO: 16'e göre 3'e kadar amino asit modifikasyonlu f. SEQ ID NO: 22'ye göre 3'e kadar amino asit modifikasyonlu bir SEQ ID NO: 22 sekansi, burada peptidin, insan GIP reseptöründe ve insan GLP-l reseptöründe agonist aktivite sergiler ve peptit, GIP reseptörüne karsi insan GLP-l reseptörü için 100 kattan daha az seçicilige sahip olmasidir.
- 11. Bir dimer veya multimer olup, özelligi; önceki istemlerden herhangi birine ait iki veya daha fazla peptit veya peptit analogu içermesidir.
- 12. Bir konjugat olup, özelligi; önceki istemlerden herhangi birine ait peptit veya peptit analogu ve bir konjugat parçasini içermesidir.
- 13. Bir farmasötik bilesim olup, özelligi; Istemler 1-10'dan herhangi birine ait bir peptit veya peptit analogunu, Istem ll'in bir dimeri veya multimerini, Istem 12'nin bir konjugatini veya bunlarin bir kombinasyonunu ve farmasötik olarak kabul edilebilir bir tasiyici, seyreltici veya eksipiyani içermesidir.
- 14. Istemler 1 ila 10'dan herhangi birine ait bir peptit veya peptit analogu, Istem ll'in bir dimeri veya multimeri veya Istem 12'nin bir konjugati olup, Özelligi; ihtiyaci olan bir kiside kilo alimini azaltma veya kilo kaybini tetiklemede kullanim için veya Istem 1-10'dan herhangi birine göre bir peptit veya peptit analogunun, Istem ll'in bir dimeri veya multimerinin veya Istem l2'ye ait bir konjugatin kilo alimini azaltmak veya kilo kaybini indüklemek için bir ilacin hazirlanmasinda kullanimi için olmasidir.
- 15. Istemler 1 ila 10'dan herhangi birine ait bir peptit veya peptit analogu, Istem ll'in bir dimeri veya multimeri, Istem 12'nin bir konjugati olup, özelligi; diyabetin tedavisinde kullanim için olmasidir.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261662874P | 2012-06-21 | 2012-06-21 | |
| US201361787973P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201808818T4 true TR201808818T4 (tr) | 2018-07-23 |
Family
ID=48692696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2018/08818T TR201808818T4 (tr) | 2012-06-21 | 2013-06-18 | Gip reseptör aktivitesi sergileyen glukagon analogları. |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US9868772B2 (tr) |
| EP (1) | EP2864350B1 (tr) |
| JP (1) | JP6300239B2 (tr) |
| KR (1) | KR20150039748A (tr) |
| CN (1) | CN104583233B (tr) |
| AR (1) | AR091478A1 (tr) |
| AU (1) | AU2013277372B2 (tr) |
| BR (1) | BR112014031671A2 (tr) |
| CA (1) | CA2877127A1 (tr) |
| CL (1) | CL2014003421A1 (tr) |
| CO (1) | CO7170125A2 (tr) |
| CR (1) | CR20150015A (tr) |
| DK (1) | DK2864350T3 (tr) |
| EA (1) | EA029025B1 (tr) |
| ES (1) | ES2674946T3 (tr) |
| HR (1) | HRP20180936T1 (tr) |
| HU (1) | HUE039267T2 (tr) |
| IL (1) | IL236386B (tr) |
| MX (1) | MX356000B (tr) |
| MY (1) | MY185217A (tr) |
| PE (1) | PE20150863A1 (tr) |
| PH (1) | PH12014502857A1 (tr) |
| PL (1) | PL2864350T3 (tr) |
| PT (1) | PT2864350T (tr) |
| RS (1) | RS57347B1 (tr) |
| SG (1) | SG11201408491SA (tr) |
| SI (1) | SI2864350T1 (tr) |
| TR (1) | TR201808818T4 (tr) |
| TW (1) | TWI644920B (tr) |
| WO (1) | WO2013192130A1 (tr) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104583218B (zh) | 2012-04-26 | 2018-04-24 | 百时美施贵宝公司 | 作为蛋白酶活化受体4(par4)抑制剂用于治疗血小板聚集的咪唑并噻二唑和咪唑并吡嗪的衍生物 |
| SI2864350T1 (en) * | 2012-06-21 | 2018-08-31 | Indiana University Research And Technology Corporation | GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| SI2934568T1 (en) | 2012-12-21 | 2018-03-30 | Sanofi | Dual GLP1 / GIP or trigonal agonists GLP1 / GIP / glucagon |
| UA118558C2 (uk) | 2013-05-28 | 2019-02-11 | Такеда Фармасьютікал Компані Лімітед | Пептидна сполука |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
| WO2015095684A1 (en) * | 2013-12-20 | 2015-06-25 | Indiana University Research And Technology Corporation | Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides |
| TW201625669A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| US20160114000A1 (en) | 2014-10-24 | 2016-04-28 | Merck Sharp & Dohme Corp. | Co-agonists of the glucagon and glp-1 receptors |
| TW201639878A (zh) | 2014-12-30 | 2016-11-16 | 韓美藥品股份有限公司 | 具有改善之安定性的升糖素衍生物 |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| HUE066226T2 (hu) | 2015-06-30 | 2024-07-28 | Hanmi Pharmaceutical Co Ltd | Glükagon származék és annak hosszú hatású konjugátumát tartalmazó készítmény |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| EA201891469A1 (ru) | 2015-12-23 | 2018-12-28 | Дзе Джонс Хопкинс Юниверсити | Агонист длительного действия glp-1r как терапия для лечения неврологических и нейродегенеративных патологических состояний |
| RS63541B1 (sr) * | 2015-12-31 | 2022-09-30 | Hanmi Pharm Ind Co Ltd | Trojni aktivator koji aktivira glukagonski, glp-1 i gip receptor |
| US10501516B2 (en) | 2016-05-24 | 2019-12-10 | Takeda Pharmaceutical Company Limited | Peptide compound |
| AU2017289014B2 (en) | 2016-06-29 | 2019-12-05 | Hanmi Pharm. Co., Ltd. | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof |
| TW201833132A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物 |
| AR110301A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip |
| JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
| CN109836488B (zh) * | 2017-11-24 | 2022-08-23 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的胰高血糖素类似物 |
| WO2019197466A1 (en) | 2018-04-10 | 2019-10-17 | Sanofi-Aventis Deutschland Gmbh | Method for cleavage of solid phase-bound peptides from the solid phase |
| AU2019250362B2 (en) | 2018-04-10 | 2025-11-06 | Sanofi-Aventis Deutschland Gmbh | Lixisenatide synthesis with capping |
| TWI707865B (zh) * | 2018-05-04 | 2020-10-21 | 丹麥商諾佛 儂迪克股份有限公司 | Gip衍生物及其用途 |
| TW202015735A (zh) | 2018-05-30 | 2020-05-01 | 法商賽諾菲公司 | 包含ｇｌｐ－１／升糖素／ｇｉｐ三重受體促效劑、連接子及透明質酸之接合物 |
| MY197569A (en) * | 2018-07-23 | 2023-06-25 | Lilly Co Eli | Gip/glp1 co-agonist compounds |
| US11166910B2 (en) * | 2019-01-25 | 2021-11-09 | Nordiccan A/S | Cannabinoid chewing gum with sugar alcohols |
| EP4112637A4 (en) * | 2020-02-24 | 2024-04-03 | Shenzhen Turier Biotech Co., Ltd. | POLYPEPTIDE COMPOUND AND ITS APPLICATION IN THE PREVENTION OR TREATMENT OF DIABETES OR A COMPLICATION OF DIABETES |
| PH12022552562A1 (en) * | 2020-03-25 | 2022-12-19 | Takeda Pharmaceuticals Co | Qd dosing of gip receptor agonist peptide compounds and uses thereof |
| CN113493503B (zh) * | 2020-04-08 | 2022-08-05 | 浙江道尔生物科技有限公司 | 一种肠促胰岛素类似物及其制备方法和用途 |
| TWI801942B (zh) | 2020-07-22 | 2023-05-11 | 丹麥商諾佛 儂迪克股份有限公司 | 適用於口服的glp-1及gip受體共促效劑 |
| CN114621327B (zh) * | 2020-12-10 | 2023-08-18 | 江苏中新医药有限公司 | GLP-1、GIP和Gcg多重受体激动蛋白质 |
| CN118184764A (zh) | 2020-12-23 | 2024-06-14 | 浙江道尔生物科技有限公司 | 一种长效胰高血糖素衍生物 |
| CN117120462A (zh) * | 2021-01-22 | 2023-11-24 | 深圳市图微安创科技开发有限公司 | 多肽化合物在预防或治疗炎症性肠病及其相关的肠纤维化中的应用 |
| US20230203100A1 (en) * | 2021-07-16 | 2023-06-29 | Pep2Tango Therapeutics Inc. | Compositions including multi-agonist peptides and methods of manufacture and use |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| CN115536739B (zh) * | 2022-07-04 | 2023-04-14 | 北京惠之衡生物科技有限公司 | 一种glp-1受体和gcg受体共激动多肽衍生物的制备方法 |
| JP7402574B1 (ja) | 2023-03-15 | 2023-12-21 | 株式会社合同資源 | α－ヨード置換カルボン酸 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| IN165717B (tr) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤 |
| US6303144B1 (en) | 1998-02-10 | 2001-10-16 | Welfide Corporation | Preparations with controlled release |
| GB2344287A (en) | 1998-12-03 | 2000-06-07 | Ferring Bv | Controlled release pharmaceutical formulation |
| SE0302312D0 (sv) * | 2002-10-04 | 2003-08-27 | Forskarpatent I Syd Ab | Peptide-based passive immunization therapy for treatment of atherosclerosis |
| ATE458534T1 (de) | 2002-10-04 | 2010-03-15 | Microchips Inc | Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US7846445B2 (en) | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
| WO2007133747A2 (en) | 2006-05-15 | 2007-11-22 | Wisconsin Alumni Research Foundation | PULMONARY DELIVERY OF 1α,25-DIHYDROXYVITAMIN D3 AND CO-ADMINISTRATION OF PARATHYROID HORMONE OR CALCITONIN |
| FR2902092B1 (fr) | 2006-06-07 | 2008-09-05 | Sapelem Soc Par Actions Simpli | Appareil de manutention de charge |
| GEP20135944B (en) * | 2007-02-15 | 2013-10-25 | Indiana Unversity Research And Tech Corporation | Glucagon/glp-1 receptor co-agonists |
| MX2009011275A (es) | 2007-04-19 | 2009-11-02 | Dong A Pharm Co Ltd | Una composicion de microesferas biodegradables adecuadas para la liberacion controlada de peptido de control de la glucosa y formulacion de la misma. |
| EP2185701A4 (en) | 2007-08-15 | 2011-03-02 | Amunix Operating Inc | COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES |
| CN102105159B (zh) | 2008-06-17 | 2015-07-08 | 印第安纳大学研究及科技有限公司 | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 |
| TWI474832B (zh) * | 2008-06-17 | 2015-03-01 | Univ Indiana Res & Tech Corp | 胰高血糖素／ｇｌｐ-１受體共同激動劑 |
| PE20120332A1 (es) | 2008-12-19 | 2012-04-14 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida |
| RU2012101274A (ru) | 2009-06-16 | 2013-07-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Соединения глюкагона, активные в отношении рецептора gip |
| MX2012008603A (es) | 2010-01-27 | 2013-01-25 | Univ Indiana Res & Tech Corp | Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad. |
| JP6121323B2 (ja) * | 2010-05-13 | 2017-05-10 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド |
| MX2012014576A (es) * | 2010-06-24 | 2013-02-21 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida. |
| KR20140043793A (ko) * | 2011-06-22 | 2014-04-10 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/glp-1 수용체 공동-작용물질 |
| SI2723367T1 (sl) * | 2011-06-22 | 2017-08-31 | Indiana University Research And Technology Corporation | Koagonisti receptorja glukanona/GLP-1 |
| SI2864350T1 (en) * | 2012-06-21 | 2018-08-31 | Indiana University Research And Technology Corporation | GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR |
| JP6657230B2 (ja) * | 2014-09-24 | 2020-03-04 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | インクレチン−インスリンコンジュゲート |
-
2013
- 2013-06-18 SI SI201331079T patent/SI2864350T1/en unknown
- 2013-06-18 EP EP13731246.8A patent/EP2864350B1/en not_active Not-in-force
- 2013-06-18 CN CN201380043984.5A patent/CN104583233B/zh not_active Expired - Fee Related
- 2013-06-18 PT PT137312468T patent/PT2864350T/pt unknown
- 2013-06-18 KR KR20157001447A patent/KR20150039748A/ko not_active Abandoned
- 2013-06-18 SG SG11201408491SA patent/SG11201408491SA/en unknown
- 2013-06-18 AR ARP130102143 patent/AR091478A1/es unknown
- 2013-06-18 CA CA2877127A patent/CA2877127A1/en not_active Abandoned
- 2013-06-18 RS RS20180728A patent/RS57347B1/sr unknown
- 2013-06-18 PE PE2014002465A patent/PE20150863A1/es not_active Application Discontinuation
- 2013-06-18 EA EA201590065A patent/EA029025B1/ru not_active IP Right Cessation
- 2013-06-18 JP JP2015518506A patent/JP6300239B2/ja not_active Expired - Fee Related
- 2013-06-18 TR TR2018/08818T patent/TR201808818T4/tr unknown
- 2013-06-18 HR HRP20180936TT patent/HRP20180936T1/hr unknown
- 2013-06-18 HU HUE13731246A patent/HUE039267T2/hu unknown
- 2013-06-18 AU AU2013277372A patent/AU2013277372B2/en not_active Ceased
- 2013-06-18 BR BR112014031671A patent/BR112014031671A2/pt not_active Application Discontinuation
- 2013-06-18 MY MYPI2014003510A patent/MY185217A/en unknown
- 2013-06-18 ES ES13731246.8T patent/ES2674946T3/es active Active
- 2013-06-18 MX MX2014015556A patent/MX356000B/es active IP Right Grant
- 2013-06-18 PL PL13731246T patent/PL2864350T3/pl unknown
- 2013-06-18 US US14/408,813 patent/US9868772B2/en not_active Expired - Fee Related
- 2013-06-18 TW TW102121585A patent/TWI644920B/zh not_active IP Right Cessation
- 2013-06-18 DK DK13731246.8T patent/DK2864350T3/en active
- 2013-06-18 WO PCT/US2013/046229 patent/WO2013192130A1/en not_active Ceased
-
2014
- 2014-12-17 CL CL2014003421A patent/CL2014003421A1/es unknown
- 2014-12-21 IL IL236386A patent/IL236386B/en active IP Right Grant
- 2014-12-22 PH PH12014502857A patent/PH12014502857A1/en unknown
-
2015
- 2015-01-19 CO CO15009514A patent/CO7170125A2/es unknown
- 2015-01-19 CR CR20150015A patent/CR20150015A/es not_active Application Discontinuation
-
2017
- 2017-12-04 US US15/830,158 patent/US20180105569A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201808818T4 (tr) | Gip reseptör aktivitesi sergileyen glukagon analogları. | |
| JP2015528795A5 (tr) | ||
| RU2015101697A (ru) | Аналоги глюкагона, обладающие активностью рецептора gip | |
| JP2014507402A5 (tr) | ||
| RU2012101274A (ru) | Соединения глюкагона, активные в отношении рецептора gip | |
| HRP20170890T1 (hr) | Suagonisti glukagonskog/glp-1 receptora | |
| ME03709B (me) | Fuzijski proteini | |
| JP2015521622A5 (tr) | ||
| CA2777758C (en) | Peptidic glp-2 agonists | |
| ES2688708T3 (es) | Análogos de glucagón acilados | |
| JP2014525901A5 (tr) | ||
| RU2012136450A (ru) | Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения | |
| JP2012530145A5 (tr) | ||
| HRP20140616T1 (hr) | Peptidni analog oksintomodulina | |
| AR094181A1 (es) | Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon | |
| JP2016500682A5 (tr) | ||
| RU2012105355A (ru) | Производное аналога glp-1 или его фармацевтически приемлемые соли и их применение | |
| JP2013518115A5 (tr) | ||
| CA2797089A1 (en) | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity | |
| JP2011524418A5 (tr) | ||
| WO2009158704A3 (en) | Therapeutic agents comprising elastin-like peptides | |
| RU2016101711A (ru) | Высокостабильный т-клеточный рецептор и способ его получения и применения | |
| CN106232616A (zh) | 两亲性合成抗菌肽、其药物组合物及其用途 | |
| CA2774593A1 (en) | Oxytocin receptor agonists | |
| BR112013032088A2 (pt) | "polipeptídeo, composição farmacêutica e seu uso" |